Gilpin Wealth Management’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Gilpin Wealth Management’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$201K	Hold	1,273	–	–	0.14%	131
2026 Q2	$201K	Buy	1,273 +8	+0.6%	+$1.08K	0.14%	132
2026 Q1	$162K	Buy	1,265 +10	+0.8%	+$1.25K	0.13%	133
2025 Q4	$153K	Buy	+1,255	New	+$144K	0.12%	134

Other funds holding XBI

LHWM

Lake Hills Wealth Management Austin, Texas $218M AUM 31.66% 1-Year Est. Return

AIC

Ayalon Insurance Company Ramat Gan, Israel $1.2B AUM 25.57% 1-Year Est. Return

MWA

MFA Wealth Advisors Pittsburgh, Pennsylvania $589M AUM 19.71% 1-Year Est. Return

MAM

Marotta Asset Management Charlottesville, Virginia $589M AUM 14.57% 1-Year Est. Return

FFA

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

BCG

Breakwater Capital Group Paramus, New Jersey $844M AUM 15.36% 1-Year Est. Return

VFA

Valeo Financial Advisors Carmel, Indiana $4.74B AUM 19.15% 1-Year Est. Return

BONH

Bank of New Hampshire Laconia, New Hampshire $463M AUM 23.57% 1-Year Est. Return

VAG

VisionPoint Advisory Group Dallas, Texas $636M AUM 21.4% 1-Year Est. Return

WAM

Worth Asset Management Dallas, Texas $343M AUM 29.82% 1-Year Est. Return

Gilpin Wealth Management's XBI Position: Q3 2026 in Review

Gilpin Wealth Management held its State Street SPDR S&P Biotech ETF (XBI) position steady in Q3 2026 at 1,273 shares worth $201K. The position accounts for 0.14% of the portfolio, ranked #131.

Gilpin Wealth Management first reported a position in XBI in Q4 2025 and has held it in 4 quarters since. The position peaked at $201K in Q2 2026. 39 funds tracked by Wall St. Rank hold XBI as of Q3 2026.

Gilpin Wealth Management held 1,273 shares of State Street SPDR S&P Biotech ETF worth $201K as of Q3 2026.
Gilpin Wealth Management left its State Street SPDR S&P Biotech ETF share count unchanged in Q3 2026.
State Street SPDR S&P Biotech ETF made up 0.14% of Gilpin Wealth Management's portfolio in Q3 2026, its #131 holding.
Gilpin Wealth Management first reported a position in State Street SPDR S&P Biotech ETF in Q4 2025 and has held it in 4 quarters since.
Gilpin Wealth Management's State Street SPDR S&P Biotech ETF position peaked at $201K in Q2 2026.
39 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q3 2026.

Based on Gilpin Wealth Management's 13F filing for Q3 2026, filed 9 Oct 2026.